Skip to content

Study · Animal study (in vivo) · rat · 1988

3 results

Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats.

Pulvirenti L, Kastin AJ

European journal of pharmacology1 Jul 1988Cited by 16 (Europe PMC)

PMID2901971 (opens in a new tab)DOI10.1016/0014-2999(88)90810-2 (opens in a new tab)PepBankPUB-02901971
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, MIF‑1 produced a significant anti-immobility effect in the behavioral despair test.

    In plain wordsIn rats, MIF‑1 significantly reduced immobility in a behavioral despair test.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseImmobility
    Study

    ratn: not reported in source

    behavioral despair test
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    0.01 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    MIF-1 and Tyr-MIF-1, at the small dose of 0.01 mg/kg i.p. (24, 5 and 1 h before the test), produced a significant anti-immobility effect.
    1 context sentence
    Summary · context
    These observations prompted us to examine whether the effects of the two peptides in the behavioral 'despair' test were modulated by dopamine antagonists.

Studies that did not test the peptide alone2

In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).

  1. 02AnimalNot a test of MIF-1 (Pro-Leu-Gly-NH2) aloneAnimal study (in vivo)Mechanism

    In rats, haloperidol antagonized the anti-immobility effect of MIF‑1.

    In plain wordsIn rats, haloperidol blocked reduced immobility compared with MIF‑1 without haloperidol.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseHaloperidol antagonism of anti-immobility
    Study

    ratn: not reported in source

    behavioral despair test
    Comparator
    MIF-1 without haloperidol
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    This effect was antagonized by a single injection of either haloperidol or sulpiride, two dopamine receptor blockers.
    1 context sentence
    Summary · context
    MIF-1 and Tyr-MIF-1, at the small dose of 0.01 mg/kg i.p. (24, 5 and 1 h before the test), produced a significant anti-immobility effect.

    In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).

  2. 03AnimalNot a test of MIF-1 (Pro-Leu-Gly-NH2) aloneAnimal study (in vivo)Mechanism

    In rats, sulpiride antagonized the anti-immobility effect of MIF‑1.

    In plain wordsIn rats, sulpiride blocked reduced immobility compared with MIF‑1 without sulpiride.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseSulpiride antagonism of anti-immobility
    Study

    ratn: not reported in source

    behavioral despair test
    Comparator
    MIF-1 without sulpiride
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    This effect was antagonized by a single injection of either haloperidol or sulpiride, two dopamine receptor blockers.
    1 context sentence
    Summary · context
    MIF-1 and Tyr-MIF-1, at the small dose of 0.01 mg/kg i.p. (24, 5 and 1 h before the test), produced a significant anti-immobility effect.

    In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.